XFOR — X4 Pharmaceuticals, Inc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501697 ·
Last close
$4.00
Market Cap
$377.28M
52W High
$4.83
52W Low
$3.20
ADV30
353,809
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 2,708,000 | 2,110,000 | -20,306,000 | -20,241,000 | 270,281,000 | 216,908,000 | 101,831,000 |
| Dec 2025 | 2,568,000 | 2,204,000 | -23,699,000 | -23,925,000 | 290,461,000 | 217,049,000 | 104,171,000 |
| Sep 2025 | 1,765,000 | 1,414,000 | -27,509,000 | -29,815,000 | 163,555,000 | 69,632,000 | 101,936,000 |
| Jun 2025 | 1,973,000 | 1,647,000 | -26,232,000 | -25,741,000 | 105,168,000 | 39,220,000 | 101,197,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-85,618,000
Investing CF
$8,154,000
Financing CF
$233,132,000
CapEx
$-3,133,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-594,554,000
Inventory
$4,479,000
Receivables
$573,000
ST Investments
$35,949,000
EBIT TTM
$-70,282,000
Pretax Income TTM
$-79,158,000
Interest Exp TTM
$8,876,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,014,000
EBITDA
$-89,685,000
Free Cash Flow
$-55,171,752
Enterprise Value
$224,584,576
Total Cash
$233,720,000
Total Debt
$77,253,000
Shares Out
94,319,696
Trailing EPS
$-2.08
Book Value
$1.79
ROE
-104.2%
ROA
-28.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,113,000 | -86,883,000 | -79,199,000 | 290,461,000 | 104,171,000 | — | -85,618,000 |
| Dec 2024 | 2,557,000 | -141,401,000 | -37,450,000 | 146,447,000 | 124,298,000 | — | -130,901,000 |
| Dec 2023 | 0 | -107,522,000 | -101,167,000 | 147,258,000 | 96,159,000 | — | -96,512,000 |
| Dec 2022 | 0 | -88,078,000 | -93,867,000 | 155,586,000 | 81,535,000 | — | -77,102,000 |
TTM Snapshot
Revenues TTM
$560,000
NetIncome TTM
$-36,696,000
OpCashFlow TTM
$0
Assets (Latest)
$146,447,000
Forward EPS
$-0.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | $379.83M | $4.60 | — |
| ARTV | Artiva Biotherapeutics, Inc. | $372.67M | $7.67 | — |
| CCCC | C4 Therapeutics, Inc. | $385.88M | $3.49 | — |
| IPSC | Century Therapeutics, Inc. | $391.37M | $2.17 | — |
| CMPX | Compass Therapeutics, Inc. | $396.19M | $2.20 | — |
News headlines (Yahoo Finance, 1h cache)
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress
2026-05-21 04:33 · Yahoo
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now
2026-05-20 13:55 · Yahoo
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know
2026-05-18 16:00 · Yahoo
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now
2026-05-14 17:39 · Yahoo
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 12:25 · Yahoo
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-06 11:15 · Yahoo
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
2026-05-05 12:25 · Yahoo
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union
2026-04-29 11:00 · Yahoo
One X4 Pharmaceuticals Insider Raised Their Stake In The Previous Year
2026-04-09 13:47 · Yahoo
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-01 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.